<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115968</url>
  </required_header>
  <id_info>
    <org_study_id>SCSAT_protocol_version 1.0</org_study_id>
    <nct_id>NCT05115968</nct_id>
  </id_info>
  <brief_title>Single Cell Sequencing of Tonsillar Tissue in Children With OSA</brief_title>
  <official_title>Single Cell Sequencing to Examine the Pathogenesis of Adenotonsillar Hypertrophy in Children With Obstructive Sleep Apnoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnoea (OSA) in children is a prevalent sleep disorder, and is&#xD;
      characterised by repetitive complete or partial upper airway obstruction during sleep. It is&#xD;
      an important disease as it is associated with a large spectrum of end-organ morbidities.&#xD;
&#xD;
      Adenotonsillar hypertrophy is the commonest cause of OSA in children, however, the cause of&#xD;
      the lymphoid tissue hypertrophy in some individuals but not the others remains unknown. To&#xD;
      address the cellular heterogeneity and immune cell involvement in adenotonsillar hypertrophy,&#xD;
      here, we propose to employ single-cell sequencing analysis to identify the cell-specific&#xD;
      expression patterns associated with the disease, which will enhance our understanding of the&#xD;
      pathogenesis of tonsillar hypertrophy in children with OSA and may provide directions for&#xD;
      development of novel therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tonsil cell characteristics</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Cells characteristics by single-cell sequencing of the adenotonsillar tissue in children with OSA.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obstructive Sleep Apnea of Child</condition>
  <arm_group>
    <arm_group_label>OSA case</arm_group_label>
    <description>Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Non-OSA subjects (with PSG OAHI &lt;1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tonsillectomy</intervention_name>
    <description>Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI &lt;1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>OSA case</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tonsillar tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Case: Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and&#xD;
        polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour),&#xD;
        with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be&#xD;
        recruited as cases.&#xD;
&#xD;
        Control: Non-OSA subjects (with PSG OAHI &lt;1/hour) who undergo adenotonsillectomy for other&#xD;
        reasons such as recurrent tonsillitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case: Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and&#xD;
        polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour),&#xD;
        with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be&#xD;
        recruited as cases.&#xD;
&#xD;
        Control: Non-OSA subjects (with PSG OAHI &lt;1/hour) who undergo adenotonsillectomy for other&#xD;
        reasons such as recurrent tonsillitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Previous upper airway surgery, genetic or syndromal disease, congenital or acquired&#xD;
        neuromuscular disease, congenital or acquired immunodeficiency, known metabolic syndrome,&#xD;
        craniofacial abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate C Chan, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate C Chan, MBChB</last_name>
    <phone>35052840</phone>
    <email>katechan@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elly Cheung</last_name>
    <phone>35052840</phone>
    <email>ellycheung@cuhk.edu.hk</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Kate Ching Ching Chan</investigator_full_name>
    <investigator_title>Clinical Professional Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

